Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00442650
Recruitment Status : Completed
First Posted : March 2, 2007
Last Update Posted : November 21, 2016
Information provided by:
Merck KGaA